Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for mild to moderate childhood allergic asthma
ChiCTR2000041572Phase 4Recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of omalizumab in allergic asthma (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoints: Global Evaluation of Treatment Effectiveness (GETE) and Children Asthma Control Test (C-ACT). Started Jan 2021; status: recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on ChiCTR2000041572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041572.